Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and Minimally Invasive Evacuation Strategies Advance Acute Care | DelveInsight

DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Trials increasingly pursue rapid hemostatic agents, targeted neuroprotectants, and device-based minimally invasive clot evacuation to shorten disability and lower mortality.

Hemostatic and anti-expansion strategies (reversal agents, factor concentrates, and novel transferrable hemostats) aim to stabilize patients early and reduce hematoma growth - a prime driver of outcomes. Parallel programs test neuroprotective drugs designed to limit perihematomal edema and inflammatory injury during the subacute window. Endovascular and minimally invasive surgical technologies (catheter-based aspiration, thrombolytic-assisted evacuation) are being validated to remove clot burden with less collateral damage.

Early-phase neurorestorative approaches (stem cell therapies, biologics) and biomarker-guided patient selection are entering feasibility trials, seeking to enhance recovery beyond acute stabilization. Regulatory interactions and adaptive trial designs are accelerating readouts for promising agents and devices, while emphasis on time-to-treatment and streamlined neurocritical-care pathways is shaping trial inclusion and endpoints.

The clinical trial ecosystem includes academic stroke centers, device manufacturers, and biotech firms advancing hemostatic agents, neuroprotectants, and MIS evacuation systems. Upcoming pivotal readouts across device and drug programs will be decisive in defining next-generation acute ICH/SAH care and expanding market opportunities for life-saving interventions.

Explore the full pipeline analysis for brain hemorrhage and uncover key opportunities @ https://www.delveinsight.com/report-store/brain-hemorrhage-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Brain Hemorrhage Pipeline Report
• DelveInsight's brain hemorrhage pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for brain hemorrhage treatment.
• The leading brain hemorrhage companies include Jiangsu Simcere Pharmaceutical Co., Ltd., AegisCN, NeurOp, Inc., Capricor Therapeutics, aptaTargets, Novartis Pharmaceuticals, Evgen Pharma, BIT Pharma, Acasti Pharma Inc., and others are evaluating their lead assets to improve the brain hemorrhage treatment landscape.
• Key brain hemorrhage pipeline therapies in various stages of development include Edaravone Dexborneol, CN 105, NP10679, Cardiosphere-Derived Exosomes, ApTOLL, BAF312, SFX-01, Nicardipine, GTX-104, and others.
• In June 2024, the FDA granted 510(k) approval to Heuron, a South Korean medical AI firm, for its Heuron ICH solution, an advanced tool for detecting cerebral bleeding through non-contrast CT scans.
• In May 2024, Heuron, a South Korean AI startup specializing in brain and neurological disorders, announced that its Heuron ICH non-contrast CT imaging analysis solution had received FDA 510(k) clearance. This marks the first FDA approval for an AI-based brain disorder analysis solution from Korea for computer-aided triage and notification devices (CADt).
• In February 2024, Viz.ai received FDA 510(k) clearance for its Viz ICH Plus algorithm, designed to automate the identification, labeling, and volume quantification of brain structures on non-contrast CT scans. The software helps analyze intracranial hyperdensities, lateral ventricles, and midline shift, providing critical volume measurements of brain bleeds to support timely treatment decisions.

Request a sample and discover the recent breakthroughs happening in the brain hemorrhage pipeline landscape @ https://www.delveinsight.com/report-store/brain-hemorrhage-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Hemorrhage Overview
A brain hemorrhage, also known as a brain bleed or intracranial hemorrhage, is a serious medical emergency involving bleeding within the brain. Since the brain is enclosed within the skull, any bleeding can exert pressure on brain tissue, potentially causing significant damage. While brain hemorrhages can occur at any age, they are most commonly seen in older adults. Symptoms often include sudden numbness, weakness, tingling, or paralysis-typically affecting one side of the body. These events disrupt communication between nerve cells and other body parts, impairing normal functions. Complications can vary depending on the hemorrhage's size, location, and the extent of brain swelling. Treatment strategies are tailored to these factors to minimize damage and support recovery.

Find out more about brain hemorrhage medication @ https://www.delveinsight.com/report-store/brain-hemorrhage-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Hemorrhage Treatment Analysis: Drug Profile
CN 105: AegisCN
CN 105 is a five-amino-acid peptide that mimics apolipoprotein E (apoE), currently being developed by AegisCN (formerly CereNova) for the treatment of cerebral hemorrhage. This neuroprotective candidate is in Phase II clinical trials and aims to reduce brain damage following hemorrhagic stroke.

NP10679: NeurOp, Inc.
NeurOp is advancing NP10679, a selective NMDA receptor inhibitor targeting the GluN2B subunit, for central nervous system (CNS) disorders. This agent is designed to block excessive glutamate signaling-a key factor in neurological conditions such as stroke, subarachnoid hemorrhage (SAH), treatment-resistant depression, and pain. NP10679's potency in acidic environments and subtype specificity may offer neuroprotection with reduced side effects compared to existing NMDA receptor antagonists.

Learn more about the novel and emerging brain hemorrhage pipeline therapies @ https://www.delveinsight.com/report-store/brain-hemorrhage-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Hemorrhage Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Brain Hemorrhage Pipeline Report
• Coverage: Global
• Key Brain Hemorrhage Companies: Jiangsu Simcere Pharmaceutical Co., Ltd., AegisCN, NeurOp, Inc., Capricor Therapeutics, aptaTargets, Novartis Pharmaceuticals, Evgen Pharma, BIT Pharma, Acasti Pharma Inc., and others.
• Key Brain Hemorrhage Pipeline Therapies: Edaravone Dexborneol, CN 105, NP10679, Cardiosphere-Derived Exosomes, ApTOLL, BAF312, SFX-01, Nicardipine, GTX-104, and others.

Dive deep into rich insights for drugs used for brain hemorrhage treatment; visit @ https://www.delveinsight.com/report-store/brain-hemorrhage-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Brain Hemorrhage Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Brain Hemorrhage Pipeline Therapeutics
6. Brain Hemorrhage Pipeline: Late-Stage Products (Phase III)
7. Brain Hemorrhage Pipeline: Mid-Stage Products (Phase II)
8. Brain Hemorrhage Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.